New research from Ludwig-Maximilians-Universität München (LMU) reveals that improper handling of the neurotransmitter dopamine within brain cells may play a critical role in worsening symptoms of Parkinson’s disease. The discovery provides fresh insights into how the disease damages neurons and points toward potential new treatment strategies.
Parkinson’s disease gradually destroys neurons that produce dopamine, a chemical vital for smooth and controlled movement. As these neurons deteriorate, patients experience tremors, stiffness, and slowed movement. The new study shows that when dopamine isn’t packaged correctly inside nerve cells, it can oxidize and become toxic, harming the very cells it’s meant to help.
Researchers found that this faulty packaging stems from two key problems: a shortage of cellular energy in the form of ATP, and reduced activity of a protein called VMAT2, which normally sequesters dopamine safely inside vesicles. Without enough ATP or VMAT2, dopamine leaks into the cellular environment and begins a harmful chain reaction.
In addition to toxic dopamine buildup, the team observed increased aggregation of α-synuclein, a protein that forms characteristic clumps known as Lewy bodies in Parkinson’s patients. The research suggests that oxidized dopamine may exacerbate α-synuclein aggregation, further damaging neurons.
Lead researcher Professor Lena Burbulla explained that the findings connect energy deficits within neurons to two major features of Parkinson’s disease, dopamine toxicity and protein aggregation revealing a previously underappreciated driver of disease progression.
Importantly, the study also found that supplying ATP directly to affected neurons helped restore healthy dopamine packaging and stopped the cell damage in laboratory models. This raises hopes that therapies aimed at restoring cellular energy balance or enhancing VMAT2 function could slow or prevent neurodegeneration in Parkinson’s.
The research was published in the journal Science Advances and highlights how cutting-edge cellular models, such as patient-derived stem cells, can deepen understanding of complex neurological diseases and speed up translational research.
